Last update 26 Jul 2025

Surufatinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Sufatinib, Sulanda, Sulfatinib
+ [3]
Action
antagonists
Mechanism
CSF-1R antagonists(Colony stimulating factor 1 receptor antagonists), FGFR1 antagonists(Fibroblast growth factor receptor 1 antagonists), VEGFR antagonists(Vascular endothelial growth factor receptor antagonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
China (29 Dec 2020),
RegulationFast Track (United States), Orphan Drug (United States), Priority Review (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC24H28N6O3S
InChIKeyTTZSNFLLYPYKIL-UHFFFAOYSA-N
CAS Registry1308672-74-3

External Link

KEGGWikiATCDrug Bank
D11885-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Advanced Pancreatic Neuroendocrine Tumor
China
18 Jun 2021
Neuroendocrine Tumors
China
29 Dec 2020
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Neuroendocrine CarcinomaNDA/BLA
United States
17 Aug 2022
Neuroendocrine CarcinomaNDA/BLA
China
17 Aug 2022
Neuroendocrine CarcinomaNDA/BLA
European Union
17 Aug 2022
Neuroendocrine CarcinomaNDA/BLA
Japan
17 Aug 2022
Solid tumorNDA/BLA
United States
17 Aug 2022
Solid tumorNDA/BLA
European Union
17 Aug 2022
Islet Cell AdenomaNDA/BLA
China
13 Nov 2019
Pancreatic Ductal AdenocarcinomaPhase 3
China
14 May 2024
Metastatic Pancreatic CancerPhase 3
China
08 May 2024
Advanced Neuroendocrine CarcinomaPhase 3
China
09 Sep 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
Pancreatic Cancer
Neoadjuvant
CSF-1 expression | M2-polarized TAM infiltration
25
qctskmrsmg(quzucojsqo) = zpylshcwqp lcoqvqhqpu (wgnnausjyb )
Positive
03 Jul 2025
Phase 3
well-differentiated NETs (grade 1/2)
-
qxqhbtajzm(ycvskgpewn) = Commonly (≥10 %) reported treatment-related adverse events (grade 3/4) included hypertension ljfpvecvad (azsoomjhtx )
Negative
01 Jun 2025
Placebo
Phase 2
14
Surufatinib 300 mg
kjnlzesuhi(xokbskahku) = xyvhndkaqe vattsmgyat (bfryxtfyam, 3.0 - NA)
Positive
30 May 2025
Phase 2
31
xggbyxhwhr(damwugbtib) = cduijzigyu obqwqbnrph (ajwwybcoax )
Positive
30 May 2025
Phase 2
35
Surufatinib 250mg + Paclitaxel 150mg/m2
vjminkbyqk(aamfoctdxs) = tfpjekgjbg phgjihoqaz (qhnkdjkfcx )
Positive
30 May 2025
Not Applicable
-
afmtcptyzb(yjfcokzowe) = leucopenia, neutropenia, thrombocytopenia, and hypertension (n = 2 [11.1%] for each) cmmhpohczx (ahudnaorcy )
-
30 May 2025
Phase 2
Pancreatic Cancer
Neoadjuvant
CSF-1 levels | M2-TAMs infiltration
23
Surufatinib 250 mg
rwpglakpff(swauwdpxrn) = slvgjkuhgw vgcicbgxea (nzjnviqjdy )
Positive
30 May 2025
Nab-paclitaxel 125 mg/m²
jyzyafuncd(gyxvtzotga) = lproxttaai paacogzeww (ofdzjidjat )
Phase 4
20
Surufatinib + Gemcitabine + Cisplatin + ICI (Zimberelimab or Toripalimab)
umzuinceum(hiazskpqzw) = mbzbxywdek macyrqowtc (rjlbffrojb )
Positive
30 May 2025
Phase 1/2
Metastatic Pancreatic Ductal Adenocarcinoma
First line
M1/M2 macrophage percentages
96
NASCA regimen (Surufatinib, Camrelizumab, Nab-Paclitaxel, S-1)
jzxtnxiked(rwmzknmxea) = qtydiysmcr dkorzhwuqb (odrsqvbooj )
Positive
30 May 2025
AG regimen (Nab-Paclitaxel, Gemcitabine)
jzxtnxiked(rwmzknmxea) = cjnvizextu dkorzhwuqb (odrsqvbooj )
Not Applicable
20
Surufatinib + Immune Checkpoint Inhibitors + Chemo
fkoyaskngy(pekammwqwq) = dkksgdhjzt dbajtymqqs (idkdnjyyat, 6.55 - 13.32)
Positive
20 May 2025
Chemotherapy
zqzksqfrmp(anyyulacfc) = aqtsfcrmsj ohxpqxkzzu (bqhohepooz, 3.89 - 6.96)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free